Tomás Pascual

5.4k citations
133 papers · 1.6k indexed · 1 hit paper · h-index 19

Tomás Pascual

117 papers receiving 1.6k citations

Hit Papers

Frequency and spectrum of PIK3CA somatic mutations in bre...227202020262022202450100150200

Peers

Tomás Pascual
Comparison fields: 5 of 104
  • Oncology 1.0k
  • Cancer Research 488
  • Pulmonary and Respiratory Medicine 585
  • Immunology 230
  • Genetics 97
Replace Ryuichi Mizuno with:
Ryuichi Mizuno Japan
Nicola Battelli Italy
Yasuhide Miyoshi Japan
Kenei Furukawa Japan
Tom Wei‐Wu Chen Taiwan
Hiroyuki Fujikawa Japan
Riccardo Giampieri Italy
Mireille Mousseau France
Katsunobu Oyama Japan
Junichiro Hiro Japan
Tomás Pascual relative to Ryuichi Mizuno Japan Ryuichi Mizuno's profile →
Citations per field
00.5×1.5×2.4×
Ryuichi Mizuno · 1×
Citations per year

Countries citing papers authored by Tomás Pascual

Since Specialization
Citations

This map shows the geographic impact of Tomás Pascual's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomás Pascual with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomás Pascual more than expected).

Fields of papers citing papers by Tomás Pascual

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomás Pascual. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomás Pascual. The network helps show where Tomás Pascual may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tomás Pascual, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tomás Pascual Line = papers co-authored together Tomás Pascual links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20241
3 20247
4 20244
5 20240
6 20248
7 20241
8 20247
9 202429
10 20231
11 20231
12 20231
13 202336
14 20224
15 20218
16 20205
17 20209
18 20190
19 201976
20 2017277

About Tomás Pascual

Tomás Pascual is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 133 papers that have together received 1.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (70 papers), HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (54 papers), Cancer Treatment and Pharmacology (25 papers), Cancer Immunotherapy and Biomarkers (23 papers), Estrogen and related hormone effects (12 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Oncology (1.0k citations), Cancer Research (488 citations) and Pulmonary and Respiratory Medicine (585 citations). Tomás Pascual has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Aleix Prat, Patricia Galván, Fara Brasó‐Maristany, Montserrat Muñoz-Mateu, Laia Paré, María Vidal, Francesco Schettini, Bárbara Adamo, Núria Chic and Eva Ciruelos. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026